SGLT2 vs DPP4 Inhibitor: Which Protects Liver Better in T2D?
SGLT2 inhibitors did not reduce the risk for adverse liver outcomes more than DPP-4 inhibitors in patients with type 2 diabetes and metabolic dysfunction–associated steatotic liver disease.
Medscape Medical News
source https://www.medscape.com/viewarticle/sglt2-vs-dpp-4-inhibitor-which-protects-liver-better-t2d-2024a1000fcz?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/sglt2-vs-dpp-4-inhibitor-which-protects-liver-better-t2d-2024a1000fcz?src=rss
Comments
Post a Comment